Table 2 Multivariate analysis adjusted for potentially significant covariates in subset of N = 71
Covariates | Time to CRPC, HR (95%CI) | P-value | OS, HR (95%CI) | P-value |
|---|---|---|---|---|
PSA levels ≥ 261 ng/mL | 1.16 (0.61–2.22) | 0.656 | 2.71 (0.55–13.26) | 0.219 |
Gleason score, 8 or higher | 3.55 (1.46–9.89) | 0.004 | 7.58 (0.75–76.94) | 0.087 |
N stage | 1.58 (0.87–2.96) | 0.138 | 3.93 (0.98–15.73) | 0.053 |
Visceral metastasis | 1.98 (0.93–4.03) | 0.074 | 2.91 (0.51–16.71) | 0.231 |
Bone metastasis, EOD 2 or more | 2.49 (1.34–4.78) | 0.004 | 0.68 (0.18–2.65) | 0.583 |
Used BMA | 1.04 (0.57–1.88) | 0.900 | 1.17 (0.33–4.16) | 0.802 |
PSA levels after 3 months of ADT, 1% or more | 2.07 (1.14–3.82) | 0.017 | 13.18 (2.34–74.38) | 0.004 |